Analyst Consensus ?
ConsensusBuy12 ratings
Bullish12100.0%
Neutral00.0%
Bearish00.0%
BrightSpring Health Services, Inc. Common Stock · BTSG · FY2026 Q2 · Calendar Q3 2026
BrightSpring posts strong Q2 growth and maintains FY 2026 guidance
The supplied analysis supports a constructive but qualified view: strong demand in specialty pharmacy, infusion, home health, and provider services is supporting growth, while IRA headwinds, generic competition, integration execution, and M&A flexibility temper the outlook.
Reported Before market openNASDAQHealthcare
$13.24B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.45
Consensus $0.40
EPS surprise
+13.6%
Reported versus consensus
Reported revenue
$3.87B
Consensus $3.66B
Revenue surprise
+5.8%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-18.1%
Event window
SPY move
+0.7%
Same window
Abnormal move
-18.8%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
-1.0%
Up to 20 sessions
BTSGSPY benchmark
Ask FN2 about BTSG FY2026 Q2
Transcript, numbers and history already loaded
Why did BTSG fall 18.1% after beating EPS estimates in FY2026 Q2?What changed in BTSG's guidance and outlook in FY2026 Q2?Give me the bull and bear case for BTSG after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Q2 analysis indicates that growth remained strong and broad-based, while management maintained FY 2026 guidance. The quarter also added credit-rating upgrades, further LDD expansion, and continued progress integrating Amedisys and LHC assets to the prior-quarter narrative.
Guidance delta
Maintained. Management's FY 2026 outlook calls for 17–19.5% revenue growth and 32.8–36.8% adjusted EBITDA growth.
Key takeaways
- Revenue and adjusted EBITDA growth was broad-based across Pharmacy Solutions and Provider Services, according to the supplied analysis.
- Specialty and infusion LDD launches, home-health demand, and Amedisys/LHC integration remain central growth drivers.
- Management highlighted AI and automation, credit-rating upgrades, and expansion into additional states while retaining a disciplined M&A approach.
Management priorities
- Expand oncology and rare-disease LDD programs and acute and chronic infusion services.
- Integrate Amedisys and LHC assets while extending quality and home-health capabilities.
- Invest in AI-driven automation and evaluate capital structure alongside disciplined M&A opportunities.
Follow BTSG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$66.89Current
$30Low
$63.86Average
$90High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Aug 13, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 13, 2026 |
| UBS | Buy | Buy | Maintain | Jul 8, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 2, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 18, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Jun 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | May 5, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 4, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | May 4, 2026 |
| Guggenheim | Buy | Buy | Maintain | Oct 1, 2024 |
Named analyst price targets
Upside is calculated against the persisted current price $66.89. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Deutsche Bank | Analyst unavailable | $70 | $60.82 | +4.6% | Aug 3, 2026 |
| Morgan Stanley | Analyst unavailable | $80 | $70 | +19.6% | Jul 14, 2026 |
| KeyBanc | Analyst unavailable | $80 | $69.64 | +19.6% | Jul 14, 2026 |
| Wells Fargo | Stephen Baxter | $78 | $71.43 | +16.6% | Jul 13, 2026 |
| Guggenheim | Analyst unavailable | $81 | $71.43 | +21.1% | Jul 13, 2026 |
| Raymond James | Parker Snure | $80 | $71.58 | +19.6% | Jul 9, 2026 |
| UBS | Analyst unavailable | $85 | $70.44 | +27.1% | Jul 8, 2026 |
| BTIG | David Larsen | $90 | $66.25 | +34.5% | Jun 22, 2026 |
| Cowen & Co. | Analyst unavailable | $81 | $64.43 | +21.1% | Jun 18, 2026 |
| Goldman Sachs | Scott Fidel | $71 | $57.4 | +6.1% | Jun 8, 2026 |
| Morgan Stanley | Erin Wright | $71 | $59.98 | +6.1% | Jun 2, 2026 |
| BMO Capital | Analyst unavailable | $70 | $59.16 | +4.6% | May 21, 2026 |
| Morgan Stanley | Analyst unavailable | $62 | $52.44 | -7.3% | May 6, 2026 |
| Deutsche Bank | Analyst unavailable | $60 | $53.51 | -10.3% | May 4, 2026 |
| BTIG | Analyst unavailable | $65 | $52.58 | -2.8% | May 4, 2026 |
| Stephens | Analyst unavailable | $64 | $52.58 | -4.3% | May 4, 2026 |
| KeyBanc | Analyst unavailable | $60 | $52.58 | -10.3% | May 4, 2026 |
| Wells Fargo | Stephen Baxter | $61 | $52.58 | -8.8% | May 4, 2026 |
| BMO Capital | Analyst unavailable | $60 | $52.58 | -10.3% | May 1, 2026 |
| Leerink Partners | Whit Mayo | $49 | $43.82 | -26.7% | Mar 18, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $49 | $40.65 | -26.7% | Mar 2, 2026 |
| BTIG | David Larsen | $55 | $39.27 | -17.8% | Feb 2, 2026 |
| BMO Capital | Analyst unavailable | $46 | $39.6 | -31.2% | Jan 23, 2026 |
| Mizuho Securities | Ann Hynes | $45 | $39.1 | -32.7% | Jan 9, 2026 |
| Wells Fargo | Analyst unavailable | $43 | $40.67 | -35.7% | Jan 7, 2026 |
| BTIG | Analyst unavailable | $50 | $38 | -25.3% | Dec 23, 2025 |
| Mizuho Securities | Analyst unavailable | $42 | $35.58 | -37.2% | Dec 18, 2025 |
| KeyBanc | Matthew Gillmor | $45 | $35.89 | -32.7% | Dec 12, 2025 |
| Stephens | Analyst unavailable | $44 | $35.23 | -34.2% | Dec 10, 2025 |
| Wells Fargo | Stephen Baxter | $39 | $33.91 | -41.7% | Nov 12, 2025 |
| Mizuho Securities | Ann Hynes | $38 | $34.47 | -43.2% | Oct 29, 2025 |
| BTIG | David Larsen | $41 | $34 | -38.7% | Oct 29, 2025 |
| UBS | Analyst unavailable | $42 | $34.44 | -37.2% | Oct 29, 2025 |
| Jefferies | Brian Tanquilut | $36 | $31.89 | -46.2% | Oct 21, 2025 |
| Mizuho Securities | Analyst unavailable | $32 | $29.45 | -52.2% | Oct 17, 2025 |
| Morgan Stanley | Analyst unavailable | $32 | $28.85 | -52.2% | Oct 14, 2025 |
| Wells Fargo | Stephen Baxter | $33 | $28.87 | -50.7% | Oct 7, 2025 |
| Deutsche Bank | Pito Chickering | $30 | $25.48 | -55.2% | Sep 8, 2025 |
| Mizuho Securities | Ann Hynes | $26 | $21.82 | -61.1% | May 5, 2025 |
Track every rating change on BTSG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance. Patients receive care from a dedicated team of clinical professionals and licensed pharmacists. Formerly known as Phoenix Parent Holdings Inc., the company officially adopted the name BrightSpring Health Services, Inc. in May 2021. Founded in 1974, its headquarters are located in Louisville, Kentucky.
Historical context
All BTSG earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
| RMD ResMed Inc. | FY2027 Q1 · Calendar Q4 2026 | +8.2% | -9.1% | ResMed reaffirms FY27 outlook as products and digital health support growth |
Latest beats and misses
Who reports nextBeat on EPS
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
- ABBVFY2026 Q3 · October 30, 2026+2.4% EPS+1.4% move
- GDFY2026 Q3 · October 30, 2026+9.0% EPS+0.5% move
- MGAFY2026 Q3 · October 30, 2026+15.8% EPS-1.4% move
Missed on EPS
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
Get the BTSG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T19:07:55.449171+00:00
- FN2 earnings calendar · 2026-09-05T01:23:14.965082+00:00
- Polygon adjusted daily market bars · 2026-10-31T09:00:42.524369+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T09:00:42.521632+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.